Skip to content
香港聯合腫瘤中心
  • Cancer diagnosis
    • Physical examination
      • Male/Female physical examination plan
    • Endoscopic examination
    • X-ray
    • Ultrasound examination
    • Laboratory examination
    • Cytological examination
    • Pathological diagnosis
    • Positron emission tomography and computed tomography (PET/CT)
    • Magnetic resonance imaging (MRI)
    • Computed tomography (CT) scan
    • Genetic testing
  • Cancer treatment
    • Information for newly diagnosed patients
    • Surgery
    • Radiotherapy
    • Chemotherapy
      • Side Effect
      • Chemotherapy Instructions
      • cancer cell characteristics, and individual constitution.
    • Gene-directed targeted therapy
    • Targeted therapy
    • Hormone therapy
    • Immunotherapy
    • Hyperbaric oxygen therapy
      • Sudden hearing loss
      • Ischemic stroke / Cerebral stroke
      • Diabetic foot ulcers
      • Applications in oncology
  • Types of cancer
    • What is cancer
    • breast cancer
    • Lung cancer
      • Lung cancer articles and reports
    • colorectal cancer
    • liver cancer
    • stomach cancer
    • prostate cancer
    • thyroid cancer
    • brain cancer
    • nasopharyngeal cancer
    • cervical cancer
    • pancreatic cancer
    • Uterine body cancer
  • Cancer information
    • New cancer drugs
      • Lung cancer drugs
      • Breast cancer drugs
      • Bile duct cancer drugs
      • Liver cancer drugs
      • Bowel cancer drugs
      • Urothelial carcinoma drugs
      • Prostate cancer drugs
    • News report
    • Cancer information video
    • Medical lectures
    • Doctor Q&A
  • Clinical research
  • Contact us
    • Contact methods
    • Join us
  • 繁
  • En
  • Cancer diagnosis
    • Physical examination
      • Male/Female physical examination plan
    • Endoscopic examination
    • X-ray
    • Ultrasound examination
    • Laboratory examination
    • Cytological examination
    • Pathological diagnosis
    • Positron emission tomography and computed tomography (PET/CT)
    • Magnetic resonance imaging (MRI)
    • Computed tomography (CT) scan
    • Genetic testing
  • Cancer treatment
    • Information for newly diagnosed patients
    • Surgery
    • Radiotherapy
    • Chemotherapy
      • Side Effect
      • Chemotherapy Instructions
      • cancer cell characteristics, and individual constitution.
    • Gene-directed targeted therapy
    • Targeted therapy
    • Hormone therapy
    • Immunotherapy
    • Hyperbaric oxygen therapy
      • Sudden hearing loss
      • Ischemic stroke / Cerebral stroke
      • Diabetic foot ulcers
      • Applications in oncology
  • Types of cancer
    • What is cancer
    • breast cancer
    • Lung cancer
      • Lung cancer articles and reports
    • colorectal cancer
    • liver cancer
    • stomach cancer
    • prostate cancer
    • thyroid cancer
    • brain cancer
    • nasopharyngeal cancer
    • cervical cancer
    • pancreatic cancer
    • Uterine body cancer
  • Cancer information
    • New cancer drugs
      • Lung cancer drugs
      • Breast cancer drugs
      • Bile duct cancer drugs
      • Liver cancer drugs
      • Bowel cancer drugs
      • Urothelial carcinoma drugs
      • Prostate cancer drugs
    • News report
    • Cancer information video
    • Medical lectures
    • Doctor Q&A
  • Clinical research
  • Contact us
    • Contact methods
    • Join us
  • 繁
  • En

Category: 子宮內膜癌

Application of Dostarlimab combination therapy in advanced endometrial cancer

Dostarlimab聯合治療方案在晚期子宮內膜癌中的應用 在2024年婦科腫瘤學會(SGO)年會上，RUBY/ENGOT-EN6/GOG3031/N

立即閱讀
July 4, 2025 No Comments

Immunotherapy combined with chemotherapy significantly improves survival in advanced/recurrent endometrial cancer: Important data from the RUBY and NRG-GY018 trials released. Dostarlimab

免疫聯合化療顯著改善晚期/復發性子宮內膜癌存活期：RUBY與NRG-GY018試驗重要數據公佈 在2024年SGO年會上公佈的RUBY和NRG-GY0

立即閱讀
July 4, 2025 No Comments

Expert Opinion: Dr. Gini F. Fleming Discusses a New Landscape in Immunotherapy for Endometrial Cancer: Dostarlimab

專家觀點：Gini F. Fleming博士談子宮內膜癌免疫治療新格局 在2024年SGO年會上，芝加哥大學婦科腫瘤醫學主任Gini F. Flemi

立即閱讀
July 4, 2025 1 Comment

NCCN Clinical Practice Guidelines in Oncology: Key Updates for 2024 - Dostarlimab

NCCN腫瘤學臨床實踐指南：2024年更新要點 美國國家綜合癌症網絡（NCCN®）於1996年首次發布《腫瘤學臨床實踐指南》（NCCN Guideli

立即閱讀
July 4, 2025 No Comments

The LEAP-001 study did not meet its primary endpoint, but Lenvatinib/Pembrolizumab still showed efficacy in a specific subgroup of endometrial cancer.

LEAP-001研究未達主要終點，但Lenvatinib/Pembrolizumab仍對特定子宮內膜癌亞組顯示療效 備受矚目的ENGOT-en9/LE

立即閱讀
July 4, 2025 No Comments

The FDA expands the indication for Dostarlimab-gxly in combination with chemotherapy for endometrial cancer.

FDA擴展Dostarlimab-gxly聯合化療用於子宮內膜癌的適應症 8月1日，美國食品及藥物管理局（FDA）批准dostarlimab-gxly

立即閱讀
July 4, 2025 No Comments

Age is just a number: Treatment considerations for endometrial cancer in older women

年齡只是數字：老年女性子宮內膜癌的治療考量 疾病特徵與挑戰 子宮內膜癌好發於55-65歲女性（中位診斷年齡64歲），老年患者更常見高惡性度、深層肌層侵

立即閱讀
July 4, 2025 No Comments

AACR 2025: PD-1 inhibitor dostarlimab achieves a new breakthrough in "non-surgical" treatment of dMMR tumors

AACR 2025：PD-1抑制劑dostarlimab實現dMMR腫瘤「無手術」治療新突破 研究亮點 在2025年美國癌症研究協會（AACR）年會上

立即閱讀
July 4, 2025 No Comments

Imlunestrant monotherapy or in combination with Abemaciclib: All-oral targeted therapy for ER-positive advanced breast cancer

Imlunestrant單藥或聯合Abemaciclib：ER陽性晚期乳腺癌的全口服標靶治療 新一代實驗性口服選擇性雌激素受體降解劑（SERD）iml

立即閱讀
July 4, 2025 No Comments

The US FDA has approved Mirvetuximab Soravtansine-gynx for the treatment of FRα-positive platinum-resistant epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.

美國FDA批准Mirvetuximab Soravtansine-gynx用於FRα陽性鉑類耐藥上皮性卵巢癌、輸卵管癌或原發性腹膜癌 2023年3月2

立即閱讀
July 4, 2025 No Comments
Page1 Page2
香港聯合腫瘤中心

The Hong Kong United Oncology Centre (HKUOC) provides cancer-related medical services such as cancer screening, cancer diagnosis and cancer treatment, including immunotherapy, chemotherapy, targeted drug therapy, radiation therapy, hormone therapy and palliative care.

Contact us

  • Address: Rooms 01-06, 20/F, 238 Nathan Road, Kowloon (MTR Jordan Station Exit E)
  • Phone: +852 2386 8002
  • WhatsApp：5518 2992
  • Fax: (852) 2386 8229
  • Macau: Enquiry@hkuoc.hk

Consultation time

Monday to Friday

9:00 am to 1:00 pm

2:00 p.m. to 6:00 p.m.

Saturday

9:00 am to 1:00 pm

Closed on Sundays and public holidays

Types of cancer

  • breast cancer
  • Lung cancer
  • colorectal cancer
  • liver cancer
  • stomach cancer
  • prostate cancer
  • thyroid cancer
  • brain cancer
  • nasopharyngeal cancer
  • pancreatic cancer
  • Uterine body cancer
  • breast cancer
  • Lung cancer
  • colorectal cancer
  • liver cancer
  • stomach cancer
  • prostate cancer
  • thyroid cancer
  • brain cancer
  • nasopharyngeal cancer
  • pancreatic cancer
  • Uterine body cancer

Cancer treatment

  • Information for newly diagnosed patients
  • Surgery
  • Radiation therapy (electrotherapy)
  • Chemotherapy
  • Targeted therapy
  • Hormone therapy
  • Immunotherapy
  • Information for newly diagnosed patients
  • Surgery
  • Radiation therapy (electrotherapy)
  • Chemotherapy
  • Targeted therapy
  • Hormone therapy
  • Immunotherapy

phone

WhatsApp

Facebook